<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02169908</url>
  </required_header>
  <id_info>
    <org_study_id>LIPIDOXA</org_study_id>
    <nct_id>NCT02169908</nct_id>
  </id_info>
  <brief_title>Analysis of Chronic Neuropathic Pain Markers in Patients Treated With Oxaliplatin</brief_title>
  <acronym>LIPIDOXA</acronym>
  <official_title>LIPIDOXA, a Pilot Study of Analysis of Chronic Neuropathic Pain Markers in Patients Treated With Oxaliplatin-based Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Hospitalier Paris Saint Joseph</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Hospitalier Paris Saint Joseph</source>
  <brief_summary>
    <textblock>
      The role of oxidative stress in the development of oxaliplatin-induced peripheral neuropathy
      has been previously described in mice and in neuronal cell cultures (Massicot 2013); clinical
      manifestations and pathophysiological mechanisms potentially involved have also been
      described in humans (Andreas 2007) (Attal 2009).

      The investigators team plans to conduct a translational clinicobiological research to explain
      the nature of the biochemical and molecular mechanisms of the development of
      oxaliplatin-induced painful neuropathy. To perform this project, the investigators propose to
      realize a pilot study in patients newly treated with oxaliplatin. This will be conducted in
      the oncology department of Paris Saint Joseph Hospital from May 2014 until the inclusion of
      20 patients.

      The main objective of this pilot study is to evaluate the occurrence of acute and chronic
      neuropathic pain occurring in patients newly treated with oxaliplatin. The characterization
      of this pain is based on validated tests (Cruccu 2010).

      Moreover, the biochemical changes related to oxidative stress and those related to cellular
      lipid composition are characterized in these patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thermal thresholds</measure>
    <time_frame>Three to six months</time_frame>
    <description>Four thermal thresholds are assessed by a Thermotest (Somedic AB):
cold perception threshold
warm perception threshold
cold pain threshold
warm pain threshold</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tactile sensitivity</measure>
    <time_frame>Three to six months</time_frame>
    <description>Tactile sensitivity is assessed with von Frey hairs.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Characterization of pain neuropathy</measure>
    <time_frame>Three to six months</time_frame>
    <description>Neuropathic Pain Symptom Inventory (NPSI questionnaire) is used.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Digestive Cancer</condition>
  <condition>Gynecological Cancer</condition>
  <arm_group>
    <arm_group_label>Occurrence of painful neuropathy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Assessment of neuropathic pain with two devices (Thermotest and von Frey hairs) and with the Neuropathic Pain Symptom Inventory.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thermotest</intervention_name>
    <arm_group_label>Occurrence of painful neuropathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>von Frey hairs</intervention_name>
    <arm_group_label>Occurrence of painful neuropathy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient newly traeted with oxaliplatin

          -  Patient suffering from any type of cancer treated with oxaliplatin

          -  Man or Woman over 18

        Exclusion Criteria:

          -  Patient with brain or leptomeningeal metastases

          -  Patient previously treated with cisplatin

          -  Patient addicted to alcohol

          -  Diabetic patient with peripheral neurological disorders

          -  Patient receiving calcium or magnesium salts intravenously

          -  Patient suffering from peripheral neuropathy

          -  Patient suffering from psychiatric disorders

          -  Patient treated with at least one of the following drug: venlafaxine, carbamazepine,
             gabapentin, pregabalin, clomipramine, amitriptyline, imipramine, duloxetine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Massicot F, Hache G, David L, Chen D, Leuxe C, Garnier-Legrand L, Rat P, Laprévote O, Coudoré F. P2X7 Cell Death Receptor Activation and Mitochondrial Impairment in Oxaliplatin-Induced Apoptosis and Neuronal Injury: Cellular Mechanisms and In Vivo Approach. PLoS One. 2013 Jun 27;8(6):e66830. doi: 10.1371/journal.pone.0066830. Print 2013.</citation>
    <PMID>23826152</PMID>
  </reference>
  <reference>
    <citation>Binder A, Stengel M, Maag R, Wasner G, Schoch R, Moosig F, Schommer B, Baron R. Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system. Eur J Cancer. 2007 Dec;43(18):2658-63. Epub 2007 Sep 12.</citation>
    <PMID>17855072</PMID>
  </reference>
  <reference>
    <citation>Attal N, Bouhassira D, Gautron M, Vaillant JN, Mitry E, Lepère C, Rougier P, Guirimand F. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009 Aug;144(3):245-52. doi: 10.1016/j.pain.2009.03.024. Epub 2009 May 19.</citation>
    <PMID>19457614</PMID>
  </reference>
  <reference>
    <citation>Cruccu G, Sommer C, Anand P, Attal N, Baron R, Garcia-Larrea L, Haanpaa M, Jensen TS, Serra J, Treede RD. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010 Aug;17(8):1010-8. doi: 10.1111/j.1468-1331.2010.02969.x. Epub 2010 Mar 8. Review.</citation>
    <PMID>20298428</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>March 9, 2016</last_update_submitted>
  <last_update_submitted_qc>March 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

